After that, the FDA approved the company’s updated COVID booster shot, making it available alongside shots from Moderna and ...

Including "initial doses"—those who have received only the first dose of Pfizer ... booster. As of mid-August, by which time Delta had become the dominant strain in the U.S., all three ...

Moderna beat first-quarter expectations Thursday. The news could bolster Moderna stock which is approaching its first ...

All vaccines have at least occasional side effects. But people who say they were injured by COVID vaccines believe their cases have been ignored.

An updated COVID booster shot can be expected this fall ... XBB.1.5 Omicron strain and is expected to be effective against ...

Booster shots help to "remind" it of how to respond to a virus ... for certain higher-risk individuals were also recommended. In September 2023, the FDA authorized Pfizer-BioNTech's updated vaccine ...

The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S. The ...

Ten years after dipping its toes into the gene therapy pool in a licensing deal with Spark Therapeutics, Pfizer has gained FDA approval for the acquired treatment. The U.S. regulator has endorsed ...

Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis ...

Pfizer (NYSE:PFE) said it has received FDA approval for its one-time gene therapy Beqvez for the treatment of certain adults with hemophilia B. The drugmaker said the therapy is aimed at enabling ...

Patients with moderate to severe hemophilia B can now take Pfizer’s BEQVEZ (fidanacogene elaparvovec-dzkt) with the approval of the FDA. Hemophilia B is an inherited bleeding disorder that ...